Human RCTPubMed ID: 39532060·2024

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

Frías JP, Deenadayalan S, Erichsen L, et al.

New England Journal of Medicine, 2024 · n = 751

Key finding

Tirzepatide demonstrated significantly greater weight loss (20.2% vs 13.7%) than semaglutide in direct comparison — a 47% greater effect.

Summary

Head-to-head trial showing tirzepatide 15mg produced 20.2% weight loss versus 13.7% for semaglutide 2.4mg over 72 weeks.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot

Tirzepatide Preserves Kidney Function in Type 2 Diabetes

American Journal of Kidney Diseases · 2023 · Human RCT